Gefitinib Intermediate CAS 184475-71-6 Purity >99.0% (HPLC)

Short Description:

4-(3-Chloro-4-Fluorophenylamino)-7-Methoxyquinazolin-6-ol

Synonyms: FAAH-IN-2; O-Desmorpholinopropyl Gefitinib

CAS: 184475-71-6

Purity: >99.0% (HPLC)

Appearance: Almost White to Grey Powder

Intermediate of Gefitinib (CAS: 184475-35-2) 

Contact: Dr. Alvin Huang 

Mobile/Wechat/WhatsApp: +86-15026746401    

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-(3-Chloro-4-Fluorophenylamino)-7-Methoxyquinazolin-6-ol (CAS: 184475-71-6) with high quality, intermediate of Gefitinib (CAS: 184475-35-2). Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase Gefitinib intermediates, Please contact: alvin@ruifuchem.com

Gefitinib Intermediates:

Chemical Properties:

Chemical Name 4-(3-Chloro-4-Fluorophenylamino)-7-Methoxyquinazolin-6-ol  
Synonyms FAAH-IN-2; O-Desmorpholinopropyl Gefitinib; 4-(3-Chloro-4-Fluoroanilino)-6-Hydroxy-7-Methoxyquinazoline; Gefitinib Impurity; Gefitinib Intermediate VII
CAS Number 184475-71-6
Stock Status In Stock 
Molecular Formula C15H11ClFN3O2
Molecular Weight 319.72 
Melting Point >260℃(dec.)
Density 1.489±0.06 g/cm3
COA & MSDS Available
Origin Shanghai, China
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Almost White to Grey Powder
Melting Point >260.0℃
Loss on Drying <1.00%
Related Substances
Single Impurity <1.00%
Total Impurities <1.00%
Purity / Analysis Method >99.0% (HPLC)
Test Standard Enterprise Standard
Usage Intermediate of Gefitinib (CAS: 184475-35-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

www.ruifuchem.com

184475-71-6 - Application:

4-(3-Chloro-4-Fluorophenylamino)-7-Methoxyquinazolin-6-ol (CAS: 184475-71-6) is an intermediate of Gefitinib (CAS: 184475-35-2), a metabolite of Gefitinib. Gefitinib is an antineoplastic target therapy drug with relatively high specificity that was developed by the British pharmaceutical company AstraZeneca; it is the first molecular targeted drug to be used in non-small cell lung cancer treatment. Epidermal growth factors (EGF) are a kind of polypeptide with a relative molecular mass of 6.45x103, and they can bind with epidermal growth factor receptors (EGFR) on target cell membrane surfaces to trigger biological effects.  EGFR is a type of tyrosine kinase (TK) type receptor, so when bound with EGF, it will promote TK activation in the receptor. This will cause tyrosine residue in the receptor to autophosphorylate and send continuous dividing signals into the cell, causing cell proliferation and differentiation. Gefitinib blocks the signal transduction pathway of cell surface EGFR to prevent tumor growth, metastasis, and growth in blood vessels, and it can induce tumor cell apoptosis.

  • Write your message here and send it to us